Since the epidemic first started in China in the fall of 2019, the Chinese vaccine was once unique in the world from late last year to this year. However, an analysis of the CCP’s vaccine development process reveals a series of suspicions that are not unhelpful to the international community in understanding the truth about the new crown epidemic; moreover, the CCP’s plan to produce the vaccine itself reveals another of its attempts to seek profit over harm.
I. Revelation of the starting point of the CCP’s vaccine trial
The CCP claims that the first case of the new coronavirus appeared in Wuhan on December 1, 2019, and that by January 21 there were only 440 confirmed cases nationwide; the Wuhan Health Commission’s 8th outbreak notification on January 15 said that “no clear evidence of human-to-human transmission has been found.” If this official information is true, then officials should have been unprepared for the possible globalization of the epidemic at that time.
However, a report in the Beijing Daily on March 25 of this year provided a completely opposite clue. The report mentioned that the Chinese Communist Party had identified five vaccines to deal with the epidemic in early 2020 and had begun to deploy trial production; it mentioned that one of the five vaccine technologies came from Major General Chen Wei, the Communist Party’s chief expert on biochemical weapons, and his team. This report is both enlightening and thought-provoking.
Three questions come to mind. First, if the disease-causing virus is, as the CCP claims, an accidental occurrence in nature on a small scale (the scourge of a few bats) and is not transmitted from person to person, then why is the CCP using its forces, including the military’s biological warfare unit, to develop a vaccine on a large scale? Second, the fact that the CCP was able to complete the initial development of multiple vaccines 3 weeks before the closure of Wuhan in early 2020 suggests that it knew long ago that the epidemic would spread on a large scale. If this is the case, then what is the purpose of its cover-up of the epidemic and the lie that the virus is not easily transmitted? Such lies only contributed to the rapid globalization of the epidemic. Third, in early 2020, when all five vaccines were already in the application-oriented stage (some failed to be commercialized in later trials), why not seal the city in Wuhan much earlier so that the global death toll from the spread of the epidemic would not be minimized? Anyone with common sense would have understood that the CCP’s actions at the beginning of the epidemic were extremely perverse and revealed a clear sense of mischief. Instead of trying to stop the globalization of the virus as soon as possible, it seemed to be waiting for the virus to spread globally.
Second, did the Chinese Communist Party have vaccine varieties ready before the epidemic?
Prashant Yadav, a healthcare supply chain expert at the Center for Global Development, an international think tank, notes that “vaccine manufacturing is an endeavor where an almost infinite combination must work perfectly”; there are differences in raw materials, the microorganisms needed to culture vaccines, the culture conditions under which those microorganisms grow, etc. “It’s science with established principles, but sometimes it’s more unique than art.” So it usually takes years to design the manufacturing process for a vaccine and to develop a new one. However, the Chinese Communist Party has taken the development of this vaccine in its stride.
A report in Xinhua News Agency on January 16 of this year mentioned that China’s national vaccine took only 344 days from the approval of the project to the development, construction, production and marketing. Among them, it took 98 days from the initiation of scientific and technological research to the approval of clinical trials; 78 days from the entry into the clinic to the completion of Phase I/II clinical trials in both Wuhan and Beijing institutes; and 168 days from the initiation of Phase III clinical trials to the approval of the market. This 344-day statement is based on the end point of the domestic market supply of the national vaccine on December 30, 2020, and 344 days backward, which is roughly the date of January 21 last year, i.e., the date of Wuhan’s city closure. But there is a loophole in the 344-day argument, which is that if the vaccine had not begun development by Jan. 21, 2020, where did the five vaccines identified by the CPC as available for application in early 2020 come from before then?
Vaccines for clinical trials must first complete development and trial production. The U.S. Pfizer vaccine began development on March 20 last year and took at least four months for development and trial production; the CCP’s national vaccine began clinical trials on April 12 last year, and if it really began development around January 21, then its development and trial production took only 80 days, one-third less time than Pfizer’s.
The fact that the CCP vaccine was developed and trialed much faster than the U.S. Pfizer vaccine implies two possibilities. The first possibility is that the real start of development of the CCP vaccine was not on January 21, but at an earlier moment, such as December 2019, or even November before the epidemic appeared. The second possibility is that the CCP already had a vaccine for the new coronavirus on hand, and the so-called R&D during this trial vaccine was just a formality, so it could save a lot of time. Either way, both possibilities point to the same thing, namely that the CCP was prepared for the epidemic long before it started and had a vaccine developed for it.
This indirectly suggests that the virus of the epidemic was under the control of the CCP from the beginning to the end, and was not a natural outbreak. Those who make and use poisons have the antidote in their hands; those who can make the antidote can only be those who make the poison, because others do not know what the ingredients of the poison are. The same goes for vaccines. Without a deadly virus in hand, there is naturally no way to prepare a vaccine to contain the virus early.
III. The mystery of the CCP’s rapid mass production of vaccines
There are currently seven major vaccines in the world, namely Pfizer, AZ, Johnson & Johnson/Janssen, and Modena in Europe and the U.S., Sinopharm and Kexing in China, and Covishield from the Serum Institute of India. the U.S. vaccine was to be available for public vaccination by the end of 2020, but at that time Pfizer’s vaccine capacity was very small, reaching a monthly production of 100 million doses only in March this year. But China’s mass production capacity for vaccines is almost a year ahead of the U.S.
The Pfizer vaccine in the U.S. started its R&D in late March last year, then initial trial production, then completion of Phase 3 clinical trials before and after, and finally approval and market supply, which took 9 months in between, a speed that Pfizer’s R&D staff themselves could hardly believe at first; then it took a few months for the Pfizer vaccine to reach the scale of 100 million doses of mass production per month. Thus, the combined time from the start of Pfizer’s research and development last March to the full launch of the vaccine this spring is one year.
China, on the other hand, joined the World Health Organization’s New Coronavirus Vaccine Implementation Programme on October 8, 2020, providing 92 low- and middle-income economies with funding for the vaccine and its purchase. When China joined the program, Zheng Zhongwei, head of the vaccine research and development task force of the State Council’s Joint Prevention and Control Mechanism, said that China’s annual vaccine production capacity could reach 610 million doses by the end of 2020. In other words, as early as the late summer and early fall of 2020, the mass production capacity of Chinese communist vaccines is already approaching a monthly output of hundreds of millions of doses. This is why the world vaccine supply market was dominated only by CCP vaccines in the first few months of this year, when it took almost 3 months for vaccines in Europe and the US to be manufactured from the end of 2020 to mass production. Compared with the CCP vaccine, the world vaccine supply market in Europe and the United States is late in starting and the supply is far from keeping up with the domestic and international needs, leaving a window of almost 6 months for the CCP vaccine to take the lead in the world.
Even if the Chinese Communist Party’s vaccine trial and production capacity fully reaches the level of the U.S., it is impossible to compress or speed up the process of clinical trials and the cultivation of microorganisms needed to produce vaccines. However, the time line for mass production of vaccines by the CCP reveals another problem related to the contents of the previous two sections: Since the CCP vaccines reached the scale of mass production of 100 million doses per month in early autumn last year, the time for the CCP to start the microbial culture and special raw materials and equipment such as assaying, testing, original liquid dispensing and encapsulation necessary for mass production of vaccines, based on the fastest speed of one year in the United States as a reference, can be approximately from The Chinese Communist Party’s mass production date of early fall 2020 can be rolled back to fall 2019.
The CCP claimed that the first case of the plague-causing virus appeared by chance in Wuhan on December 1, 2019, a lie disproved by its rapid mass production schedule of the vaccine. According to the above extrapolation, by the fall of 2019, the CCP not only had the new crown virus in hand, but also had the vaccine varieties available and was even preparing to mass-produce the vaccine; the assumption was that the epidemic would soon spread from China and spill over to the world. The assumption was that the epidemic would soon spread from China to the rest of the world, but the CCP did not reveal a word about it at that time, but quietly watched as the world was plunged into the epidemic, and it seems that the CCP began to wait for its “harvest” at that time.
The CCP postponed domestic vaccination in order to export large quantities of vaccines
What is the “harvest” that the CCP is waiting for? It waited for the globalization of the epidemic, which took hundreds of thousands of lives, before making a fortune from the epidemic. Therefore, when its vaccine reached mass production scale, it did not use it at home, but stockpiled hundreds of millions of doses of the vaccine and conducted clinical trials abroad to open the way for mass export of the vaccine. On July 21, 2020, the Kexin vaccine also began its Phase 3 clinical study abroad. The U.S. vaccine was still in the early stages of development at the time.
Why didn’t the Chinese Communist Party announce in June 2020 that its vaccine was about to be mass-produced? That was the point at which it scheduled its vaccine for foreign clinical trials, while at the same time, the technology and equipment conditions for mass production were already in place. Wasn’t this a great opportunity to brag about its vaccine development “achievements”? The CCP’s decision not to do so was obviously carefully considered. By then, the CCP should have taken into account two factors that prevented it from announcing the mass production of the vaccine last June. First, if it had announced the imminent mass production of the vaccine in June last year, it would have exposed the horses and made the world suspect that the CCP had prepared the vaccine before the virus spread around the world; second, the CCP had to wait until the epidemic had spread to all countries before it could grandly conduct clinical trials in some countries to obtain approval for the global sale of its vaccine.
This former factor dictates that when the vaccine is in the hands of the CCP in June 2020, despite the urgent need for the vaccine for domestic epidemic prevention, domestic vaccination cannot be launched in order to keep it secret from foreign countries; in other words, the CCP has artificially postponed the domestic vaccination of the vaccine in order to make vaccine money abroad. Taiwan’s United Daily News website reported on June 7, 2021 that by this date, the CCP had pledged to sell or donate nearly 700 million doses of vaccines to more than ninety countries.
According to Xinhua, only 10 million doses of vaccines were administered nationwide on Jan. 13, 2021. At that time, the CCP’s annual vaccine production capacity had reached 600 million doses. According to information released by the CCP’s National Health Commission, mass vaccination in China only began in March this year, and the country received only 80 million doses on March 23 this year, or one-eighth of the annual production capacity; it reached 250 million doses at the end of April; and only reached 1 billion doses on June 21 this year (some vaccines require 2 doses). Why is it March 2021 when widespread vaccination begins in the country? Because in this month, European and American vaccines start to move towards mass production stage, and European and American vaccines are far more effective than Chinese vaccines in preventing the disease. Therefore, the Chinese Communist Party seizes the “window” of several months when the mass production of vaccines in Europe and the United States has not yet started, and uses hundreds of millions of doses of vaccines for export as a priority to make money. The CCP’s policy of supplying vaccines “abroad first, then at home” reveals its sinister intention to make money from the epidemic after allowing the epidemic to globalize.
V. International sales of Chinese vaccines are muddled by unreliable clinical trials
In order to sell a large number of Chinese vaccines before the mass market of vaccines in the United States, the CCP has conducted sloppy clinical trials abroad, just to muddle through. China’s Sinopharm and Kexing vaccines completed Phase 3 clinical trials as early as early fall 2020, but the Phase 3 clinical trial report for the Sinopharm vaccine was delayed until March 2021 and published in the Journal of the American Medical Association (JAMA) on May 26, 2021. The Chinese Communist Party has already made a lot of money from the epidemic before May 26th of this year.
As soon as the Phase 3 clinical report of the national vaccine was published, it immediately raised questions in the international medical community. Bloomberg reported on May 27 of this year that the makers of the Chinese vaccine were criticized for not sharing enough data on the safety and efficacy of the vaccine. After reading the Phase 3 clinical report of the Chinese vaccine, experts in the international medical community immediately identified several problems. First, the gender ratio of the trial sample was severely skewed, with men accounting for 85% and women for only 15%; second, only 2% of the trial sample was made up of older people over 60 years of age who were most likely to be infected, with the vast majority of participants being young and middle-aged people who were relatively unlikely to be infected; and third, of the 40,832 subjects, only two were seriously infected. Thus, according to Dong Yuhong, a European virologist, such clinical trials lack sufficient data to demonstrate the vaccine’s protective power against severe infections.
The Bloomberg report notes that despite this, the World Health Organization has opened the way for China’s national vaccine to be sold worldwide; the WHO has not officially given the green light to China’s KeXing vaccine until now (because its clinical trial report was never officially published), but the CCP has sold 380 million doses worldwide.
On June 27 of this year, Voice of America published a report on a world study on the traceability of the new coronavirus that yielded three new findings: the earliest discovery of the new coronavirus in China was at least 2 months earlier than currently known, and the global spread of the virus may have occurred before the closure of Wuhan; the earliest emergence of the new coronavirus showed a surprising adaptability to the human body, and a laboratory leak could not be ruled out possibility; the destruction of the earliest virus samples by Chinese experts is seen as new evidence of an attempt to cover up the origin of the virus. The author, on the other hand, analyzed several suspicious points in the development and manufacturing process of the CCP vaccine, which are highly relevant to the new findings mentioned in the above report. The uncovering of the truth about the epidemic is moving forward step by step.